Quinn Opportunity Partners LLC Has $1.20 Million Holdings in Novavax, Inc. $NVAX

Quinn Opportunity Partners LLC lifted its position in Novavax, Inc. (NASDAQ:NVAX) by 63.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 190,118 shares of the biopharmaceutical company’s stock after acquiring an additional 74,057 shares during the quarter. Quinn Opportunity Partners LLC owned approximately 0.12% of Novavax worth $1,198,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Signaturefd LLC increased its position in Novavax by 47.2% in the 2nd quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 3,122 shares during the last quarter. Vise Technologies Inc. bought a new position in shares of Novavax in the second quarter worth about $70,000. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Novavax in the first quarter valued at approximately $71,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Novavax in the 2nd quarter worth $72,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of Novavax in the 2nd quarter worth approximately $73,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVAX has been the subject of a number of recent analyst reports. TD Cowen dropped their target price on shares of Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a research report on Tuesday, November 4th. HC Wainwright upped their price target on Novavax from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Cantor Fitzgerald began coverage on shares of Novavax in a research report on Friday, October 24th. They set an “overweight” rating and a $18.00 target price for the company. Wall Street Zen downgraded shares of Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Bank of America reiterated an “underperform” rating and set a $7.00 target price (down from $9.00) on shares of Novavax in a report on Wednesday, August 20th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $11.38.

Novavax Stock Down 3.2%

Novavax stock opened at $7.20 on Thursday. The company’s 50-day moving average price is $8.38 and its two-hundred day moving average price is $7.58. The stock has a market cap of $1.17 billion, a P/E ratio of 3.16, a P/E/G ratio of 0.12 and a beta of 2.69. Novavax, Inc. has a twelve month low of $5.01 and a twelve month high of $11.55. The company has a quick ratio of 2.34, a current ratio of 2.36 and a debt-to-equity ratio of 5.93.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.17). The business had revenue of $70.45 million during the quarter, compared to analyst estimates of $55.63 million. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The firm’s quarterly revenue was down 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.76) earnings per share. Novavax has set its FY 2025 guidance at EPS. As a group, analysts expect that Novavax, Inc. will post -1.46 EPS for the current year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.